Storage of Polyvinylpyrrolidone (PVP) in Tissues Following Long‐Term Treatment with a PVP‐Containing Vasopressin Preparation

Abstract

The parenteral use of polyvinylpyrrolidone (PVP) leads to PVP retention in humans. Four case histories dealing with patients on long-term treatment with a PVP-containing vasopressin preparation are presented, and the possibility of a harmful effect of the PVP storage is discussed. The presence of PVP in serum, demonstrated by lipoprotein electrophoresis, is described. Based on the literature and the present findings, a withdrawal of PVP-containing preparations for injectional purposes is advocated.